Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 3 (50%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 2 | 72.4% | +12.7% |
| FONTAINHAS, AURORA M | 1 | 37.5% | +48.0% |
| FRUMKIN, JESSE P | 1 | 69.8% | +46.9% |
| STEINKE, SEAN JAMES | 1 | 7.1% | -7.7% |
| EMCH, GREGORY S | 1 | 49.0% | +44.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17776743 | NUCLEIC ACID LIPID PARTICLE VACCINE ENCAPSULATING HPV MRNA | STEINKE, SEAN JAMES | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17605656 | METHOD FOR DIAGNOSING ENDOMETRIOSIS, DISEASE STATE MONITORING METHOD, AND KIT | EMCH, GREGORY S | 31d overdue |
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 22d |
| 18265617 | OPTIC NERVE PROTECTING AGENT CONTAINING ANTI-LRP1 ANTIBODY | FONTAINHAS, AURORA M | 29d |
| 17638723 | MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER | CHONG, KIMBERLY | 29d |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 34d |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1675 | 1 |
| 1685 | 1 |
| 1619 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265617 | OPTIC NERVE PROTECTING AGENT CONTAINING ANTI-LRP1 ANTIBODY | FONTAINHAS, AURORA M | 1675 | §102 | Non-Final OA | 29d | Pending | Jun 06, 2023 |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 1636 | Other | Non-Final OA | 34d | Pending | Sep 01, 2022 |
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 1685 | §103 | Non-Final OA | 22d | Pending | Jun 27, 2022 |
| 17776743 | NUCLEIC ACID LIPID PARTICLE VACCINE ENCAPSULATING HPV MRNA | STEINKE, SEAN JAMES | 1619 | §102 | Final Rejection | 9d | Pending | May 13, 2022 |
| 17638723 | MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER | CHONG, KIMBERLY | 1636 | §103 | Final Rejection | 29d | Pending | Feb 25, 2022 |
| 17605656 | METHOD FOR DIAGNOSING ENDOMETRIOSIS, DISEASE STATE MONITORING METHOD, AND KIT | EMCH, GREGORY S | 1678 | §102 | Non-Final OA | 31d overdue | Pending | Oct 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial